<DOC>
	<DOCNO>NCT00274469</DOCNO>
	<brief_summary>The purpose study compare efficacy tolerability Faslodex ( fulvestrant ) Arimidex ( anastrozole ) postmenopausal woman hormone receptor positive advance breast cancer .</brief_summary>
	<brief_title>A Clinical Trial Compare Efficacy Tolerability Faslodex With Arimidex Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Confirmed hormone receptor positive advance breast cancer , postmenopausal woman Previous treatment advance breast cancer ( previous treatment early breast cancer allow ) .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>oncology</keyword>
	<keyword>cancer</keyword>
	<keyword>breast cancer</keyword>
</DOC>